The role of SGK-1 and SGK-2 in hypertension and nephropathy in diabetes mellitus

SGK-1和SGK-2在高血压和糖尿病肾病中的作用

• 批准号: LP0562243
• 负责人: Prof Carol Pollock
• 金额: $ 7.63万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-03-23 至 2008-03-22
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0562243
• 关键词: role; SGK; hypertension; nephropathy; diabetes

The key objective is to define the suitability of the serum glucocorticoid regulated kinases -1 and -2 (SGK-1, -2) as novel drug discovery targets. A specific inhibitor targeting SGK-1 and -2 will be tested to determine if it reverses the enhanced sodium reabsorption and extracellular matrix production characteristic of progressive renal failure in in vitro models models of renal disease. These inhibitors present an opportunity to control hypertension whilst simultaneously limiting fibrosis in the kidney. Renal failure is steadily increasing and is now the single largest health care cost to the community. These studies will provide the proof of concept required to ultimately bring this novel preventative therapy to the community.

主要目标是确定血清糖皮质激素调节激酶 -1 和 -2 (SGK-1, -2) 作为新药物发现靶点的适用性。将测试针对 SGK-1 和 -2 的特异性抑制剂，以确定它是否可以逆转肾病体外模型中进行性肾衰竭的钠重吸收增强和细胞外基质产生特征。这些抑制剂提供了控制高血压同时限制肾脏纤维化的机会。肾衰竭正在稳步增加，目前已成为社区最大的医疗保健费用。这些研究将提供最终将这种新型预防性疗法推向社区所需的概念证明。